Oral salbutamol for symptomatic relief in mild bronchiolitis a double blind randomized placebo controlled trial.
OBJECTIVE
To determine the efficacy of oral salbutamol for providing symptomatic relief in mild bronchiolitis.


METHODS
Randomized double-blind placebo controlled trial.


METHODS
Pediatric Outpatient Department of a tertiary care hospital.


METHODS
140 infants (of 310 approached) with a clinical diagnosis of acute bronchiolitis with respiratory rate <or= 70 breath/min, heart rate <or= 200 beats/min, hemoglobin oxygen saturation (SpO2) >or= 95% in room air, no or mild accessory muscle use, and respiratory distress assessment instrument (RDAI) score <or=10. Children were followed up for 14 days.


METHODS
Oral salbutamol (0.1 mg/kg/dose) (n=70) or placebo (n=70) three times a day for 7 days or till complete resolution of symptoms,whichever was earlier.


METHODS
Time for resolution of illness (ROI), duration of fever, cough,coryza, noisy breathing, time to achieve normal feeding and normal sleep, and frequency of hospitalization and adverse effects.


RESULTS
Median (SE, 95% CI) duration of resolution of overall illness was similar in the two groups [6 (0, 5 to 7) d in the salbutamol group vs. 5 (1, 4 to 6) days in placebo group; P=0.21]. There was no significant difference in mean duration of fever, cough, coryza, noisy breathing, time to achieve normal feeding and normal sleep; and frequency of hospitalization or adverse effects, between the two groups.However, tremors were observed in 5 infants in the salbutamol group.


CONCLUSIONS
Oral salbutamol is not superior to placebo in reducing the duration of symptoms in mild cases of acute bronchiolitis in children.
Gupta
Pankaj
P
Department of Pediatrics, University College of Medical Sciences, Delhi 110 095, India.
Aggarwal
Anju
A
Gupta
Piyush
P
Sharma
K K
KK
D000208:Acute Disease; D000284:Administration, Oral; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001988:Bronchiolitis / Q000150:complications* / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D007223:Infant; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome
D001993:Bronchodilator Agents; D000420:Albuterol